Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (-βlactamase positive and -βlactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 921-925

  Stucki, A ^a   Cottagnoud, M ^b   Acosta, F ^b   Egerman, U ^c   Lauffer J ^d   Cottagnoud, Philippe ^e  

^a Clinic for Pneumology and Rehabilitation   (Switzerland)

^b Clinic for Internal Medicine   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Janssen EMEA   (Switzerland)

^e Klinik Sonnenhof   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CEFEPIME; CEFTOBIPROLE MEDOCARIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; ESCHERICHIA COLI; GRAM NEGATIVE FACULTATIVELY ANAEROBIC RODS; HAEMOPHILUS INFLUENZAE; INFLAMMATION; KLEBSIELLA PNEUMONIAE; MENINGITIS; MENINX; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TESTS; RABBITS; TREATMENT OUTCOME;

EID: 84856076537     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01537-10     Document Type: Article

References (22)

1. Anonymous. 2006. Ceftobiprole medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788. Drugs R D 7:305-311.
2. Arias CA, Singh KV, Panesso D, Murray BE. 2007. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J. Antimicrob. Chemother. 60:594-598. (Pubitemid 47299874)
3. Azoulay-Dupuis E, et al. 2004. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48:1105-1111. (Pubitemid 38405461)
4. Bayston R, et al. 2010. In vitro antimicrobial activity of silver-processed catheters for neurosurgery. J. Antimicrob. Chemother. 65:258-265.
5. Blaser J, Vergeres P, Widmer AF, Zimmerli W. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134-1139.
6. Brandao RA. 2009. Surgical site infections after elective neurosurgery: a survey of 1747 patients. Neurosurgery 64:E577.
7. Chambers HF. 2005. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:884-888. (Pubitemid 40327700)
8. Cottagnoud P, Acosta F, Cottagnoud M, Tauber MG. 2002. Cefepime is efficacious against penicillin- and quinolone-resistant pneumococci in experimental meningitis. J. Antimicrob. Chemother. 49:327-330. (Pubitemid 34162624)
9. Dacey RG, Sande MA. 1974. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob. Agents Chemother. 6:437-441.
10. Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177. (Pubitemid 34031620)
11. Fritsche TR, Sader HS, Jones RN. 2008. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn. Microbiol. Infect. Dis. 61:86-95. (Pubitemid 351509753)
12. Gerber CM, Cottagnoud M, Neftel K, Tauber MG, Cottagnoud P. 2000. Evaluation of cefepime alone and in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. J. Antimicrob. Chemother. 45:63-68. (Pubitemid 30060235)
13. Gonzalez-Lopez JJ, et al. 2009. Spontaneous epidural abscess: analysis of 15 cases with emphasis on diagnostic and prognostic factors. Eur. J. Intern. Med. 20:514-517.
14. Hebeisen P, et al. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836. (Pubitemid 32182033)
15. Kosowska K, et al. 2005. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:1932-1942. (Pubitemid 40631609)
16. Louie A, et al. 2010. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob. Agents Chemother. 54:2638-2645.
17. Murthy B, Schmitt-Hoffmann A. 2008. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin. Pharmacokinet. 47:21-33. (Pubitemid 350260886)
18. Noel GJ, et al. 2008. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob. Agents Chemother. 52:37-44.
19. Rouse MS, Hein MM, Anguita-Alonso P, Steckelberg JM, Patel R. 2006. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn. Microbiol. Infect. Dis. 55:333-336. (Pubitemid 44128728)
20. Tunkel AR. 2001. Bacterial meningitis.Lippincott Williams & Wilkins, Hagerstown, MD.
21. Vaudaux P, et al. 2005. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3789-3793. (Pubitemid 41233033)
22. Yin LY, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann A. 2008. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1618-1622. (Pubitemid 351614651)